Moxifloxacin

Moxifloxacin is an orally bio-available, broad spectrum bacterial gyrase-inhibiting fluoroquinolone antibiotic [1].

Moxifloxacin at 50 μg/mL has been reported to induce a significant reduction of viable cells. A remarkable anti-proliferative activity of moxifloxacin has been proved in the concentrations between 50 and 1500 μg/mL. Moreover, moxifloxacin could lead to signs of cellular damage which were seen like binucleation in a dose-dependent manner [2].

Rats intravenously injected with moxifloxacin at 100 mg/kg have shown the increase of Serum glucose and serum epinephrine concentrations as well as the release of histamine. However, moxifloxacin at 75 mg/kg did not show any effects on serum epinephrine, glucose or histamine concentrations increase [3].

References:
[1] Iatropoulos MJ1, Jeffrey AM, Enzmann HG, von Keutz E, Schlueter G, Williams GM. Assessment of chronic toxicity and carcinogenicity in an accelerated cancer bioassay in rats of moxifloxacin, a quinolone antibiotic. Exp Toxicol Pathol. 2001 Oct;53(5):345-57.
[2] Sobolewska B1, Hofmann J, Spitzer MS, Bartz-Schmidt KU, Szurman P, Yoeruek E. Antiproliferative and cytotoxic properties of moxifloxacin on rat retinal ganglion cells. Curr Eye Res. 2013 Jun;38(6):662-9.
[3] Ishiwata Y1, Takahashi Y, Nagata M, Yasuhara M. Effects of moxifloxacin on serum glucose concentrations in rats. Biol Pharm Bull. 2013;36(4):686-90.